Раково-тестикулярный антиген MAGE-C1 / CT7 при множественной миеломе: обзор литературы
https://doi.org/10.17650/1818-8346-2020-15-4-29-37
Аннотация
Группа опухолеассоциированных антигенов, экспрессия которых в норме описана в плацентарных клетках и зародышевых клетках яичка, получила название «раково-тестикулярные антигены». В настоящее время идентифицировано более 40 семейств генов, кодирующих раково-тестикулярные антигены, и их экспрессия изучена при многих типах злокачественных заболеваний. Предполагается, что экспрессия раково-тестикулярных антигенов может способствовать развитию процесса опухолевой трансформации, в том числе и при гематологических заболеваниях. Особый интерес в патогенезе множественной миеломы представляет антиген MAGE-C1/СT7, экспрессия которого наиболее часто выявляется при данном заболевании. Согласно опубликованным данным экспрессия MAGE-C1/СT7 при множественной миеломе может выступать в качестве дополнительного маркера неблагоприятного прогноза заболевания, отражать эффективность химиотерапевтических подходов и, возможно, являться более ранним предиктором рецидива или прогрессии.
Об авторе
Э. А. Макунина
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России
Россия
Россия
Элеонора Анатольевна Макунина
125167 Москва, Новый Зыковский проезд, 4
Список литературы
1. Prideaux S.M., Conway O’Brien E., Chevassut T.J. The genetic architecture of multiple myeloma. Adv Hematol 2014;2014:864058. DOI: 10.1155/2014/864058.
2. Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12(5): 335–48. DOI: 10.1038/nrc3257.
3. Kyle R.A., Durie B.G.M., Rajkumar S.V. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24(6):1121–7. DOI: 10.1038/leu.2010.60.
4. Paszekova H., Kryukov F., Kubiczkova L. et al. High-risk multiple myeloma: different definitions, different outcomes? Clin Lymph Myel Leuk 2014;14(1):24–30. DOI: 10.1016/j.clml.2013.09.004.
5. Moreau P., Attal M., Facon T. Frontline therapy of multiple myeloma. Blood 2015;125(20):3076–84. DOI: 10.1182/blood-2014-09-568915.
6. Rajkumar S.V. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89(10):998–1009. DOI: 10.1002/ajh.23810.
7. Cavo M., Rajkumar S.V., Palumbo A. et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117(23):6063–73. DOI: 10.1182/blood-2011-02-297325.
8. Palumbo A., Rajkumar S.V., San Miguel J.F. et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;32(6):587. DOI: 10.1200/jco.2013.48.7934.
9. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121(5):749–57. DOI: 10.1046/j.1365-2141.2003.04355.x.
10. Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538–48. DOI: 10.1016/s1470-2045(14)70442-5.
11. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976;194(4260):23–8. DOI: 10.1126/science.959840.
12. Cornell R.F., Kassim A.A. Evolving paradigms in the treatment of relapsed/ refractory multiple myeloma: increased options and increased complexity. Bone Marr Transplant 2016;51(4):479–91. DOI: 10.1038/bmt.2015.307.
13. Furukawa Y., Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol 2015;20(3):413–22. DOI: 10.1007/s10147-015-0837-0.
14. Bahlis N.J. Darwinian evolution and tiding clones in multiple myeloma. Blood 2012;120(5):927–8. DOI: 10.1182/blood-2012-06-430645.
15. Clark C.A., Mosse C.A., Chen H. et al. Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. Bone Marr Transplant 2018;53(12):1589–92. DOI: 10.1038/s41409-018-0241-2.
16. Ocio E.M., Richardson P.G., Rajkumar S.V. et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014;28(3):525–42. DOI: 10.1038/leu.2013.350.
17. De Carvalho F., Vettore A.L., Colleoni G.W.B. Cancer/Testis Antigen MAGEC1/CT7: new target for multiple myeloma therapy. Clin Develop Immunol 2012; 2012. DOI: 10.1155/2012/257695.
18. Shires K., van Wyk T. The role of Cancer/ Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy. Crit Rev Oncol Hematol 2018;132:17–26. DOI: 10.1016/j.critrevonc.2018.09.010.
19. Simpson A.J.G., Caballero O.L., Jungbluth A. et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5(8):615–25. DOI: 10.1038/nrc1669.
20. Scanlan M.J., Andrew J.G., Lloyd J. Old The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4(1):1.
21. Zhang Y., Bao L., Lu J. et al. The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. Mol Cancer 2014;13(1):25. DOI: 10.1186/1476-4598-13-25.
22. He L., Ji J., Liu S. et al. Expression of cancer-testis antigen in multiple myeloma. J Huazhong Univ Sci Technolog Med Sci 2014;34(2):181–5. DOI: 10.1007/s11596-014-1255-7.
23. De Carvalho F., Alves V.L.F., Braga W.M.T. et al. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunol Immunother 2013;62(1):191–5. DOI: 10.1007/s00262-012-1376-4.
24. Wienand K., Shires K. The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma. PloS One 2015;10(3):e0120734. DOI: 10.1371/journal.pone.0120734.
25. Chen Y.T., Scanlan M.J., Sahin U. et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94(5):1914–8. DOI: 10.1073/pnas.94.5.1914.
26. Cho H.J., Caballero O.L., Gnjatic S. et al. Physical interaction of two cancer-testis antigens, MAGE-C1(CT7) and NY-ESO-1 (CT6). Cancer Immun Arch 2006;6(1):12.
27. Chen Y.T., Chadburn A., Lee P. et al. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci USA 2010;107(7):3093–8. DOI: 10.1073/pnas.0915050107.
28. Chen Y.T., Scanlan M.J., Venditti C.A. et al. Identification of cancer/testisantigen genes by massively parallel signature sequencing. Proc Natl Acad Sci USA 2005;102(22):7940–5. DOI: 10.1073/pnas.0502583102.
29. Inaoka R.J., Jungbluth A.A., Gnjatic S. et al. Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients. Cancer Immunol Immunother 2012;61(12):2207–14. DOI: 10.1007/s00262-012-1285-6.
30. Jungbluth A.A., Ely S., Di Liberto M. et al. The cancer-testis antigens CT7(MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005;106(1):167–74. DOI: 10.1182/blood-2004-12-4931.
31. Lim S.H., Austin S., Owen-Jones E. et al. Expression of testicular genes in haematological malignancies. Br J Cancer 1999;81(7):1162–4. DOI: 10.1038/sj.bjc.6690824.
32. Andrade V.C.C., Vettore A.L., Felix R.S. et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008;8:2.
33. Atanackovic D., Luetkens T., Hildebrandt Y. et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 2009;15(4):1343–52. DOI: 10.1158/1078-0432.ccr-08-0989.
34. Tyler E.M., Jungbluth A.A., Gnjatic S. et al. Cancer-Testis Antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma. Cancer Immunol Res 2014;2(6):547–58. DOI: 10.1158/2326-6066.cir-13-0174.
35. Condomines M., Hose D., Raynaud P. et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 2007;178(5):3307–15. DOI: 10.4049/jimmunol.178.5.3307.
36. Van Duin M., Broyl A., de Knegt Y. et al. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica 2011;96(11):1662–9. DOI: 10.3324/haematol.2010.037978.
37. Tinguely M., Jenni B., Knights A. et al. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci 2008;99(4):720–5. DOI: 10.1111/j.1349-7006.2008.00738.x.
38. Chen Y.T., Gure A.O., Tsang S. et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998;95(12):6919–23. DOI: 10.1073/pnas.95.12.6919.
39. Lucas S., De Smet C., Arden K.C. et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 1998;58(4):743–52.
40. De Carvalho F., Costa E.T., Camargo A.A. et al. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PloS One 2011;6(11):e27707. DOI: 10.1371/journal.pone.0027707.
41. Dhodapkar M.V., Osman K., TeruyaFeldstein J. et al. Expression of cancer/ testis (CT) antigens MAGE-A1, MAGEA3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun Arch 2003;3(1):9.
42. Shires K., Wienand K. Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients. J Cancer Res Clin Oncol 201;142(11):2383–96. DOI: 10.1007/s00432-016-2231-3.
43. Van Der Bruggen P., Traversari C., Chomez P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254(5038):1643–7. DOI: 10.1126/science.1840703.
44. Traversari C., van der Bruggen P., Luescher I.F. et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176(5):1453–7. DOI: 10.1084/jem.176.5.1453.
Рецензия
Для цитирования:
Макунина Э.А. Раково-тестикулярный антиген MAGE-C1 / CT7 при множественной миеломе: обзор литературы. Онкогематология. 2020;15(4):29-37. https://doi.org/10.17650/1818-8346-2020-15-4-29-37
For citation:
Makunina E.A. Cancer-testis antigen MAGE-C1/ CT7 in multiple myeloma: literature review. Oncohematology. 2020;15(4):29-37. (In Russ.) https://doi.org/10.17650/1818-8346-2020-15-4-29-37
Просмотров:
9564
Послать статью по эл. почте 